Anti-VEGF eye injections have transformed the treatment of diabetic retinopathy in the United Kingdom, moving from a focus on preventing total blindness to actively improving or restoring vision. These medications work by targeting a specific protein in the body that becomes overactive when the retina is deprived of oxygen. In the NHS, injections are the primary treatment for diabetic macular oedema (DMO) and are increasingly used as a complementary therapy for advanced proliferative disease. By chemically “drying up” fluid and stopping the growth of fragile vessels, anti-VEGF therapy provides a targeted approach to preserving the delicate architecture of the retina.
What We’ll Discuss in This Article
- The biological role of Vascular Endothelial Growth Factor (VEGF) in the eye.
- How anti-VEGF drugs block the “leakiness” of retinal blood vessels.
- The impact of injections on reducing central retinal thickness (Oedema).
- Why injections are preferred over laser treatment for central vision issues.
- The typical treatment cycle: Loading phase versus maintenance phase.
- Latest NICE updates regarding access to injections for UK patients.
The Science of VEGF and Retinal Damage
To understand how the injections work, it is first necessary to understand the protein they target. Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein that helps the body grow new blood vessels. However, when the retina is damaged by diabetes, the blood supply becomes restricted (ischemia). In response, the eye overproduces VEGF to signal the need for more oxygen and nutrients.
Unfortunately, the new vessels triggered by high levels of VEGF are malformed, fragile, and “leaky.” Furthermore, excessive VEGF causes existing healthy vessels to become porous, allowing fluid and proteins to seep into the retinal layers. According to research published in the British Journal of Ophthalmology, this chemical imbalance is the primary driver of both macular swelling and proliferative disease. Anti-VEGF drugs act as “sponges,” soaking up the excess protein and neutralizing its harmful effects.
Reducing Swelling and “Drying” the Retina
The most common application of anti-VEGF therapy is for diabetic macular oedema (DMO). When the macula the part of the retina used for reading swells with fluid, it distorts vision. Anti-VEGF injections rapidly tighten the junctions between the cells in the blood vessel walls, effectively “sealing” the leaks.
As the leakage stops, the body naturally reabsorbs the excess fluid already present in the retina. Specialists monitor this process using Optical Coherence Tomography (OCT) scans to measure the “central retinal thickness.” According to NICE guidelines (NG242), the goal is to reduce this thickness to a normal level, which usually results in a significant improvement in visual clarity and a reduction in distortion (wavy lines).
Stopping Abnormal Vessel Growth
In cases of proliferative retinopathy, where new vessels are growing across the retina, anti-VEGF injections can provide a rapid “rescue” effect. Because these new vessels are highly dependent on VEGF to survive, blocking the protein causes them to shrink and regress almost immediately.
While laser treatment (PRP) is still the standard for permanent stabilization of proliferative disease in the UK, injections are often used alongside laser or as a temporary measure to clear a bleed. This combination therapy helps to stabilize the retina quickly and reduces the risk of further vitreous haemorrhages. Data from Moorfields Eye Hospital suggests that using injections can also make subsequent surgeries safer by reducing the “activity” of the abnormal vessels before an operation.
The Treatment Pathway: Loading and Maintenance
Anti-VEGF treatment is not a “one-off” procedure. Because the body continues to produce VEGF as long as the underlying diabetes is present, the medication must be replenished. The standard NHS pathway typically follows two phases:
- The Loading Phase: Patients usually receive one injection every four weeks for the first three to six months. This is designed to “dry out” the retina as quickly as possible and stabilize the vision.
- The Maintenance Phase: Once the retina is dry, the specialist will move to a “Treat and Extend” or a “Pro Re Nata” (as needed) schedule. The interval between injections is gradually increased (e.g., to every 8, 12, or 16 weeks) as long as the OCT scan shows the retina remains stable.
Commonly used anti-VEGF medications in the UK include Aflibercept (Eylea), Ranibizumab (Lucentis), and Faricimab (Vabysmo). The choice of drug depends on local NHS Trust protocols and the specific severity of the patient’s condition.
Injections vs. Laser for Central Vision
Historically, focal laser was the only treatment for macular swelling. However, laser treatment works by creating tiny scars, which can sometimes lead to permanent “dim” spots in the vision. In contrast, anti-VEGF injections treat the chemical cause of the swelling without damaging the retinal tissue itself.
For this reason, injections are now the preferred first-line treatment for any swelling that involves the centre of the macula. Clinical trials have consistently shown that patients treated with injections are more likely to gain lines of vision on a sight chart compared to those treated with laser alone. In many UK clinics, laser is now reserved for “non-central” leakage or for patients who do not respond fully to injection therapy.
| Feature | Anti-VEGF Injections | Focal Laser Treatment |
| Primary Action | Blocks chemicals & dries leaks | Seals leaks with heat/burns |
| Effect on Vision | Often improves clarity | Primarily stabilizes vision |
| Tissue Impact | Non-damaging to retina | Creates microscopic scars |
| Frequency | Requires repeat visits | Often a single or few sessions |
| Main Use | Central Macular Oedema | Non-central leaks & Proliferative |
Conclusion
Anti-VEGF eye injections help diabetic retinopathy by neutralizing the proteins that cause blood vessels to leak and grow abnormally. By drying up fluid in the macula and shrinking fragile new vessels, these injections offer the best chance for stabilizing and improving vision in advanced stages of the disease. While the treatment requires a long-term commitment to regular appointments, it remains the most effective way to prevent permanent central vision loss. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
How is the injection actually given?
The eye is numbed with local anaesthetic drops, and the area is cleaned with an antiseptic. The injection is performed through the white part of the eye (the sclera) using a very fine needle. The whole process takes only a few seconds.
Will I be able to see the needle?
Most patients do not see the needle. You are usually asked to look in a specific direction, and the needle approaches from the side where it is not visible to you.
How soon will my vision improve?
Some people notice an improvement within a few days, but for most, it takes several injections (the full loading phase) to see the maximum benefit.
Are there side effects to the injections?
Common side effects include a “gritty” feeling, a small red spot on the white of the eye (a subconjunctival haemorrhage), or temporary floaters. Serious complications like infection are extremely rare.
Can I stop the injections once my vision is clear?
Only if your specialist advises it. If injections are stopped too early, the VEGF levels can rise again, causing the fluid to return and potentially damaging your vision further.
Do I still need to worry about my blood sugar?
Yes. Injections treat the symptoms of the damage in the eye, but high blood sugar continues to cause the damage. Improving your sugar levels will make the injections more effective.
Is Faricimab different from Eylea?
Faricimab is a newer type of injection that blocks two different pathways (VEGF and Ang-2), which may allow some patients to go longer between appointments compared to older drugs.
Authority Snapshot
This article explains the clinical mechanism and application of anti-VEGF injections within the UK healthcare system, incorporating 2024-2026 NICE (NG242) management standards. The content is written to meet UK medical standards and has been reviewed by the Medical Content Team to ensure alignment with NHS England and Royal College of Ophthalmologists protocols. Our goal is to help patients understand the science behind their treatment plan.
